[go: up one dir, main page]

AR057374A1 - Moduladres opioides triciclicos y composiciones farmaceuticas y veterinarias - Google Patents

Moduladres opioides triciclicos y composiciones farmaceuticas y veterinarias

Info

Publication number
AR057374A1
AR057374A1 ARP060102540A ARP060102540A AR057374A1 AR 057374 A1 AR057374 A1 AR 057374A1 AR P060102540 A ARP060102540 A AR P060102540A AR P060102540 A ARP060102540 A AR P060102540A AR 057374 A1 AR057374 A1 AR 057374A1
Authority
AR
Argentina
Prior art keywords
alkanyl
phenyl
amino
group
aminocarbonyl
Prior art date
Application number
ARP060102540A
Other languages
English (en)
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of AR057374A1 publication Critical patent/AR057374A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/14—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing 9-azabicyclo [3.3.1] nonane ring systems, e.g. granatane, 2-aza-adamantane; Cyclic acetals thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Addiction (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Otolaryngology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychology (AREA)
  • Reproductive Health (AREA)
  • Emergency Medicine (AREA)

Abstract

La presente se refiere un los compuestos de formula (1) utiles como moduladores de los receptores opioides delta y (mu). También se describen composiciones farmacéuticas y veterinarias y Kits. Estos compuestos son utiles para tratar el dolor leve un severo y diversas enfermedades utilizando los compuestos de la presente. Reivindicacion 1: Un compuesto de la formula (1), donde: R1 es hidroxi; mercapto; aminocarbonilo; alcanilC1-4-aminocarbonilo; di(alcanilC1-4)aminocarbonilo; (fenilmetílico)aminocarbonilo; (4-metoxi-fenilmetílico)aminocarbonilo; alcanilC1-4-oxicarbonilo; aminotiocarbonilo; amidino; hidroxiamidino; fenilcarbonilo; -C(=NOH)fenilo; amino; alcanilC1-4-amino; di(alcanilC1-4)amino; aminometilo; hidroximetilo; metansulfonilamino; arilC6-10-amino, donde arilo está opcionalmente sustituido con uno un tres sustituyentes seleccionados independientemente del grupo formado por alcanilo C1-6, alcoxi C1-6, halogeno, hidroxi; dihidroimidazolilo; formilamino; tioformilamino; o piridinilamino; u, opcionalmente, R1 es -S-C(NH2)=N- para formar una porcion fusionada en la cual el segundo punto de union es un átomo de carbono no puente adyacente; R2 es un sustituyente seleccionado del grupo formado por hidrogeno, alcanilo C1-8, halo1-3-alcanilo C1-8, alquenilo C2-8, alquinilo C2-8, cicloalcanilo C3-8, cicloalcanilalcanilo C1-8, alcanilC1-8-oxialcaniloC1-8, alcanilC1-8-tioalcaniloC1-8, hidroxialcanilo C1-8, alcanilC1-8-oxicarbonilo, halo1-3- alcanilC1-8-carbonilo, formilo, tioformilo, carbamimidoilo, feniliminoalcanilo C1-8, fenilalcanilo C1-8, fenilalquenilo C1-8, fenilalquinilo C1-8 naftilalcanilo C1-8 y heteroarilalcanilo C1-8, donde el heteroarilo se selecciona del grupo formado por benzo[1,3]dioxolilo, imidazolilo, furanilo, piridinilo, tienilo, indazolilo, indolilo, indolinilo, isoindolinilo, isoquinolinilo, isotiazolilo, isoxazolilo, oxazolilo, pirazinilo, pirazolilo, piridazinilo, pimidinilo, pirrolilo, quinolinilo, isoquinolinilo, tetrazolilo, tiazolilo; donde fenilo, naftilo y heteroarilo son opcionalmente sustituidos con fenilo, y de uno a tres sustituyentes seleccionados independientemente del grupo formado por alcanilo C1-6, alquenilo C2-6, alcanilC1-6oxi, amino, alcanilC1-6-amino, di(alcanilC1-6)amino, alcanilC1-6-carbonilo, alcanilC1-6-carboniloxi, alcanilC1-6-carboniloamino, alcanilC1-6-tio, alcanilC1-6-sulfonilo, halogeno, hidroxi, ciano, fluoralcanilo C1-6, tioureido, y fluoralcanilC1-6-oxi; alternativamente, cuando fenilo y heteroarilo son opcionalmente sustituidos con sustituyentes alcanilo o alcaniloxi unidos a átomos de carbono adyacentes, los dos sustituyentes pueden formar en conjunto un alcanilo o cicloheteroalcanilo cíclico fusionado seleccionado del grupo formado por -(CH2)3-5-, -O(CH2)2-4-, - (CH2)2-4O-, y -O(CH2)1-3O-; A es ausente o -(CH2)2-3-; Y es O o S; y enantiomeros, diastereomeros, tautomeros, o las sales farmacéuticamente aceptables de los mismos.
ARP060102540A 2005-06-16 2006-06-15 Moduladres opioides triciclicos y composiciones farmaceuticas y veterinarias AR057374A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US69110105P 2005-06-16 2005-06-16

Publications (1)

Publication Number Publication Date
AR057374A1 true AR057374A1 (es) 2007-11-28

Family

ID=37334600

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060102540A AR057374A1 (es) 2005-06-16 2006-06-15 Moduladres opioides triciclicos y composiciones farmaceuticas y veterinarias

Country Status (13)

Country Link
US (2) US7582650B2 (es)
EP (1) EP1896467B1 (es)
JP (1) JP2008543866A (es)
CN (1) CN101243079A (es)
AR (1) AR057374A1 (es)
AT (1) ATE490251T1 (es)
AU (1) AU2006259273A1 (es)
BR (1) BRPI0611885A2 (es)
CA (1) CA2612491A1 (es)
DE (1) DE602006018604D1 (es)
RU (1) RU2008101667A (es)
TW (1) TW200716134A (es)
WO (1) WO2006138528A2 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004253898A1 (en) 2003-06-27 2005-01-13 Janssen Pharmaceutica N.V. Tricyclic delta opioid modulators
JP2008529971A (ja) * 2004-08-05 2008-08-07 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 三環式δ−オピオイド調節剤
JP2008525482A (ja) 2004-12-22 2008-07-17 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 三環式ｏ−オピオイド調節剤
WO2006069275A1 (en) * 2004-12-22 2006-06-29 Janssen Pharmaceutica N.V. Tricyclic delta-opioid modulators
MX2007007627A (es) * 2004-12-22 2008-01-28 Johnson & Johnson Moduladores delta-opioides triciclicos.
AU2006203880A1 (en) * 2005-01-06 2006-07-13 Janssen Pharmaceutica N.V. Tricyclic delta-opioid modulators
AR057374A1 (es) 2005-06-16 2007-11-28 Janssen Pharmaceutica Nv Moduladres opioides triciclicos y composiciones farmaceuticas y veterinarias
AU2006272773B2 (en) * 2005-07-21 2012-03-08 Rensselaer Polytechnic Institute 8-carboxamido-substituted-2 , 6-methano-3-benzazocines and 3 - carboxamido- substituted morphanes as opioid receptor binding agents
MY148558A (en) * 2008-09-11 2013-04-30 Amgen Inc Spiro-tetracyclic ring compounds as betasecretase modulators and methods of use
US8420647B2 (en) 2010-01-21 2013-04-16 Hoffmann-La Roche Inc. 4-phenoxy-nicotinamide or 4-phenoxy-pyrimidine-5-carboxamide compounds
JP5584352B2 (ja) 2010-03-15 2014-09-03 アムジエン・インコーポレーテツド β−セクレターゼ調節剤としてのアミノ−ジヒドロオキサジン系およびアミノ−ジヒドロチアジン系スピロ化合物ならびにそれらの医学的用途
WO2011115938A1 (en) 2010-03-15 2011-09-22 Amgen Inc. Spiro-tetracyclic ring compounds as beta - secretase modulators
US9346827B2 (en) 2011-02-07 2016-05-24 Amgen Inc. 5-amino-oxazepine and 5-amino-thiazepane compounds as beta secretase antagonists and methods of use
WO2013003720A1 (en) 2011-06-29 2013-01-03 Alkermes, Inc. Peripherally acting opioid compounds
WO2013044092A1 (en) 2011-09-21 2013-03-28 Amgen Inc. Amino-oxazines and amino-dihydrothiazine compounds as beta-secretase modulators and methods of use
WO2014078314A1 (en) 2012-11-15 2014-05-22 Amgen Inc. Amino-oxazine and amino-dihydrothiazine compounds as beta-secretase modulators and methods of use
CN110013476A (zh) * 2019-04-08 2019-07-16 南昌大学 6-羟基-1,2,3,7-四甲氧基呫吨酮在制备促海马神经发生的药物中的应用
WO2021072083A1 (en) * 2019-10-08 2021-04-15 Marshall University Research Corporation Na/K-ATPase LIGANDS AND USE THEREOF FOR TREATMENT OF CANCER

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2368006A (en) 1943-10-07 1945-01-23 Searle & Co Heterocyclic tertiary amines
FR1159125A (fr) 1953-03-27 1958-06-23 Promonta Chem Fab Procédé pour préparer des dérivés de la phényl-thiazine présentant comme substituant basique un noyau hétérocyclique contenant un atome d'azote
US2901478A (en) 1957-02-11 1959-08-25 Promonta Chem Fab Phenothiazine compounds
US3179665A (en) 1959-12-16 1965-04-20 Wander Ag Dr A 9-(n-ethyl and n-propyl piperidyl-3'-methyl)-thioxanthenes
DE1159954B (de) 1961-11-25 1963-12-27 Boehringer & Soehne Gmbh Verfahren zur Herstellung neuer 10-(Alkoxypiperidinopropyl)-phenthiazine und ihrer Salze
DE1670118A1 (de) 1966-07-22 1970-11-05 Boehringer Mannheim Gmbh Verfahren zur Herstellung neuer Derivate des 6,11-Dihydro-dibenz[b,e]oxepins und ihrer Salze
US3470188A (en) 1967-01-05 1969-09-30 Smithkline Corp 9-cycloalkyl-lower alkyl-piperidylidene derivatives of xanthenes and thioxanthenes
NL6818027A (es) 1968-01-09 1969-07-11
GB1250534A (es) 1969-03-03 1971-10-20
US3987042A (en) 1969-03-03 1976-10-19 Claude Gueremy Phenothiazine derivative
US3931232A (en) 1974-06-24 1976-01-06 Smithkline Corporation 3-Alkyl xanthene compounds
US4086350A (en) 1974-11-06 1978-04-25 Smithkline Corporation Pharmaceutical compositions and method of producing anti-psychotic activity without extrapyramidal symptoms
ZA756550B (en) 1974-11-06 1976-09-29 Smithkline Corp Pharmaceutical compositions and method of producing antipsychotic activity without extrapyramidal symptoms
US4285956A (en) 1978-05-12 1981-08-25 Kefalas A/S Xanthene and thioxanthene derivatives, compositions thereof and treatment therewith
US4356184A (en) 1980-06-04 1982-10-26 G. D. Searle & Co. Anti-allergic or antihypertensive 1-piperidinylmethyl benzenamines
US4666907A (en) 1983-10-05 1987-05-19 Merck Frosst Canada, Inc. Phenothiazine and derivatives and analogs and use as leukotriene biosynthesis inhibitors
US4777177A (en) 1984-10-19 1988-10-11 Ciba-Geigy Corporation Pesticidal thioxanthen-9-ylidenepiperidines
FR2689013B1 (fr) 1992-03-30 1995-05-05 Rhone Poulenc Rorer Sa Nouvelle application thérapeutique des dérivés de la phénothiazine.
ZA978792B (en) 1996-10-04 1998-04-06 Novo Nordisk As N-substituted azaheterocyclic compounds.
TW548271B (en) 1996-12-20 2003-08-21 Astra Pharma Inc Novel piperidine derivatives having an exocyclic double bond with analgesic effects
SE9604786D0 (sv) 1996-12-20 1996-12-20 Astra Pharma Inc New compounds
WO1999000376A1 (en) 1997-06-25 1999-01-07 Novo Nordisk A/S Novel heterocyclic compounds
US6040318A (en) 1997-06-25 2000-03-21 Novo Nordisk A/S Tricycle substituted with azaheterocyclic carboxylic acids
EP1049676B1 (en) 1997-12-24 2005-10-12 Ortho-Mcneil Pharmaceutical, Inc. 4- aryl(piperidin-4-yl)] aminobenzamides which bind to the delta-opioid receptor
JP2003518119A (ja) 1999-12-22 2003-06-03 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド ４−［アリール（８−アザビシクロ［３．２．１］オクタン−３−イル）］アミノ安息香酸誘導体
CN1426411A (zh) 2000-03-03 2003-06-25 奥索-麦克尼尔药品公司 3－(二芳基亚甲基)－8－氮杂双环[3.2.1]辛烷衍生物
AU2001249250A1 (en) 2000-03-29 2001-10-08 Research Triangle Institute Selective ligands for the delta opioid receptor
EP1353909B1 (en) 2000-10-31 2005-04-06 Rensselaer Polytechnic Institute 8-substituted-2,6-methano-3-benzazocines and 3-substituted morphinanes as opioidreceptor binding agents
US6887876B2 (en) 2000-12-14 2005-05-03 Ortho-Mcneil Pharmaceutical, Inc. Benzamidine derivatives
US6601009B2 (en) 2001-07-12 2003-07-29 Yahoo Inc Method and system of automatic bandwidth detection
EP1306376A1 (en) 2001-10-25 2003-05-02 Biofrontera Pharmaceuticals AG Derivatives of 4-(thio- or selenoxanthene-9-ylidene)-piperidine or acridine and its use as a selective 5-HT2B receptor antagonist
US7060711B2 (en) 2001-10-25 2006-06-13 Biofrontera Bioscience Gmbh Derivatives of 4-(thio- or selenoxanthene-9-ylidene)-piperidine or acridine and its use as a selective 5-HT2B receptor antagonist
EP1321169A1 (en) 2001-12-18 2003-06-25 Biofrontera Pharmaceuticals AG Combination of a serotonin receptor antagonist with a histidine decarboxylase inhibitor as a medicament
EP1538906A2 (en) 2002-09-18 2005-06-15 Fmc Corporation Insecticidal tricyclic derivatives
AU2003301299A1 (en) 2002-10-15 2004-05-04 Janssen Pharmaceutica, N.V. Benzyl substituted (piperidin-4-yl) aminobenzamido derivatives as delta-opiod receptor modulators
CA2522199A1 (en) 2003-04-15 2004-10-28 Pfizer Products Inc. 3-benzhydrylidene-8-aza-bicyclo¬3.2.1|octane derivatives with opioid receptor activity
AU2004253898A1 (en) * 2003-06-27 2005-01-13 Janssen Pharmaceutica N.V. Tricyclic delta opioid modulators
JP2008529971A (ja) * 2004-08-05 2008-08-07 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 三環式δ−オピオイド調節剤
JP2008525482A (ja) * 2004-12-22 2008-07-17 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 三環式ｏ−オピオイド調節剤
WO2006069275A1 (en) 2004-12-22 2006-06-29 Janssen Pharmaceutica N.V. Tricyclic delta-opioid modulators
MX2007007627A (es) * 2004-12-22 2008-01-28 Johnson & Johnson Moduladores delta-opioides triciclicos.
AU2006203880A1 (en) * 2005-01-06 2006-07-13 Janssen Pharmaceutica N.V. Tricyclic delta-opioid modulators
AR057374A1 (es) 2005-06-16 2007-11-28 Janssen Pharmaceutica Nv Moduladres opioides triciclicos y composiciones farmaceuticas y veterinarias

Also Published As

Publication number Publication date
TW200716134A (en) 2007-05-01
CA2612491A1 (en) 2006-12-28
US20090275610A1 (en) 2009-11-05
DE602006018604D1 (de) 2011-01-13
CN101243079A (zh) 2008-08-13
US20060287297A1 (en) 2006-12-21
EP1896467B1 (en) 2010-12-01
WO2006138528A2 (en) 2006-12-28
BRPI0611885A2 (pt) 2010-10-05
JP2008543866A (ja) 2008-12-04
ATE490251T1 (de) 2010-12-15
RU2008101667A (ru) 2009-07-27
EP1896467A2 (en) 2008-03-12
WO2006138528A3 (en) 2007-03-15
US7582650B2 (en) 2009-09-01
AU2006259273A1 (en) 2006-12-28

Similar Documents

Publication Publication Date Title
AR057374A1 (es) Moduladres opioides triciclicos y composiciones farmaceuticas y veterinarias
AR049536A1 (es) Compuestos heterociclicos condensados con actividad inhibitoria de la proteina tirosina cinasa; una composicion farmaceutica que los contiene como principio activo y su utilizacion en el tratamiento del cancer.
BRPI0722079B8 (pt) pirimidinas 5,6-substituídas inibidoras de hiv e composição farmacêutica que as compreende
PE20171449A1 (es) Derivados de nucleosidos sustituidos utiles como agentes antineoplasicos
PE20070848A1 (es) Derivados de pirimidina como ligandos del receptor de histamina h4
AR044940A1 (es) Compuestos heterociclicos y su uso como moduladores de gamma opioides
PE20120013A1 (es) Fosforamidato derivados de guanosina compuestos nucleosidos para tratamiento de infecciones virales
AR074336A1 (es) Compuestos de arilo con sustituyentes heterociclicos y su uso
HRP20171999T1 (hr) Novi derivati aminopirimidina
AR035162A1 (es) Compuesto derivado de triazo-benzo-azulenona, composicion farmaceutica que lo comprende y su uso en la fabricacion de un agente util para inhibir la actividad parp de una enzima
AR089910A1 (es) Composiciones veterinarias orales parasiticidas que comprenden agentes activos de accion sistemica, metodos y usos de las mismas
PE20050462A1 (es) COMPUESTOS DE 5,7-DIAMINOPIRAZOLO[4,3-d]PIRIMIDINAS COMO INHIBIDORES DE LA FOSFODIESTERASA TIPO 5 (PDE-5)
PE20090288A1 (es) Derivados de quinoxalina como inhibidores de la pi3 quinasa
PE20171155A1 (es) Metodos y compuestos para tratar infecciones virales por paramyxoviridae
PE20080361A1 (es) Compuestos derivados de purina como activadores del receptor de adenosina a2a
NO20073729L (no) Heterocykliske forbindelser som CCR2B-antagonister
PE20070218A1 (es) COMPUESTOS DE CICLOALQUILO AMINO-HIDANTOINA Y USO DE ESTOS PARA LA MODULACION DE ß-SECRETASA
AR074001A1 (es) Compuestos de isoindolina y composiciones farmaceuticas y uso para tratamiento de cancer
PE20090816A1 (es) Derivados de pirrolopirimidinona como agentes ligandos de los receptores p2x3
PE20080209A1 (es) Derivados de glicina como inhibidores de prolil hidroxilasa
MX2010013768A (es) Fosfatos ciclicos de nucleosidos.
AR051410A1 (es) Derivados de pirimidina biciclicos inhibidores de vih, composiciones farmaceuticas que los commprenden, su uso en la fabricacion de medicamentos para el tratamiento del sida y un metodo para su preparacion.
PE20091306A1 (es) Pirrolopirimidinas y pirrolopiridinas
AR075366A1 (es) Compuestos heterociclicos biciclicos sustituidos como modulares de la gamma secretasa
PE20090648A1 (es) Compuestos para el tratamiento de la hepatitis c

Legal Events

Date Code Title Description
FB Suspension of granting procedure